MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

No Stability Information

Zofenil 7.5mg tablets (Imported (Ireland))

Explore other Zofenopril formulations Explore other Zofenopril 7.5mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

Incompatible

Zofran Melt 4mg oral lyophilisates (Abacus Medicine Ltd)

Explore other Ondansetron formulations Explore other Ondansetron 4mg oral lyophilisates sugar free suppliers

Stability Notes

Tablet designed to dissolve on tongue - unsuitable for MCA

Provenance

Compatibility recommendation derived from Zofran Melt 4mg oral lyophilisates (Novartis Pharmaceuticals UK Ltd).

Incompatible

Zofran Melt 4mg oral lyophilisates (CST Pharma Ltd)

Explore other Ondansetron formulations Explore other Ondansetron 4mg oral lyophilisates sugar free suppliers

Stability Notes

Tablet designed to dissolve on tongue - unsuitable for MCA

Provenance

Compatibility recommendation derived from Zofran Melt 4mg oral lyophilisates (Novartis Pharmaceuticals UK Ltd).

Incompatible

Zofran Melt 4mg oral lyophilisates (Necessity Supplies Ltd)

Explore other Ondansetron formulations Explore other Ondansetron 4mg oral lyophilisates sugar free suppliers

Stability Notes

Tablet designed to dissolve on tongue - unsuitable for MCA

Provenance

Compatibility recommendation derived from Zofran Melt 4mg oral lyophilisates (Novartis Pharmaceuticals UK Ltd).

Incompatible

Zofran Melt 8mg oral lyophilisates (Abacus Medicine Ltd)

Explore other Ondansetron formulations Explore other Ondansetron 8mg oral lyophilisates sugar free suppliers

Stability Notes

Tablet designed to dissolve on tongue - unsuitable for MCA

Provenance

Recommendation derived from Zofran Melt 8mg oral lyophilisates (Novartis Pharmaceuticals UK Ltd).

Incompatible

Zofran Melt 8mg oral lyophilisates (CST Pharma Ltd)

Explore other Ondansetron formulations Explore other Ondansetron 8mg oral lyophilisates sugar free suppliers

Stability Notes

Tablet designed to dissolve on tongue - unsuitable for MCA

Provenance

Recommendation derived from Zofran Melt 8mg oral lyophilisates (Novartis Pharmaceuticals UK Ltd).

No Stability Information

Zolinza 100mg capsules (Imported (United States))

Explore other Vorinostat formulations Explore other Vorinostat 100mg capsules suppliers

Stability Notes

There are no stability notes available for this medicine.

Incompatible

Zolmitriptan 2.5mg orodispersible tablets sugar free (A A H Pharmaceuticals Ltd)

Explore other Zolmitriptan formulations Explore other Zolmitriptan 2.5mg orodispersible tablets sugar free suppliers

Stability Notes

Orodispersible tablet, therefore unsuitable for MCA

Provenance

This compatibility recommendation is derived from Zomig Rapimelt 2.5mg orodispersible tablets (Grunenthal Ltd).

Incompatible

Zolmitriptan 2.5mg orodispersible tablets sugar free (Accord-UK Ltd)

Explore other Zolmitriptan formulations Explore other Zolmitriptan 2.5mg orodispersible tablets sugar free suppliers

Stability Notes

Orodispersible tablet, therefore unsuitable for MCA

Provenance

This compatibility recommendation is derived from Zomig Rapimelt 2.5mg orodispersible tablets (Grunenthal Ltd).

Incompatible

Zolmitriptan 2.5mg orodispersible tablets sugar free (Alliance Healthcare (Distribution) Ltd)

Explore other Zolmitriptan formulations Explore other Zolmitriptan 2.5mg orodispersible tablets sugar free suppliers

Stability Notes

Orodispersible tablet, therefore unsuitable for MCA

Provenance

This compatibility recommendation is derived from Zomig Rapimelt 2.5mg orodispersible tablets (Grunenthal Ltd).

Incompatible

Zolmitriptan 2.5mg orodispersible tablets sugar free (Crescent Pharma Ltd)

Explore other Zolmitriptan formulations Explore other Zolmitriptan 2.5mg orodispersible tablets sugar free suppliers

Stability Notes

Orodispersible tablet, therefore unsuitable for MCA

Provenance

This compatibility recommendation is derived from Zomig Rapimelt 2.5mg orodispersible tablets (Grunenthal Ltd).

Incompatible

Zolmitriptan 2.5mg orodispersible tablets sugar free (Glenmark Pharmaceuticals Europe Ltd)

Explore other Zolmitriptan formulations Explore other Zolmitriptan 2.5mg orodispersible tablets sugar free suppliers

Stability Notes

Orodispersible tablet, therefore unsuitable for MCA

Provenance

This compatibility recommendation is derived from Zomig Rapimelt 2.5mg orodispersible tablets (Grunenthal Ltd).

Incompatible

Zolmitriptan 2.5mg orodispersible tablets sugar free (Medihealth (Northern) Ltd)

Explore other Zolmitriptan formulations Explore other Zolmitriptan 2.5mg orodispersible tablets sugar free suppliers

Stability Notes

Orodispersible tablet, therefore unsuitable for MCA

Provenance

This compatibility recommendation is derived from Zomig Rapimelt 2.5mg orodispersible tablets (Grunenthal Ltd).

Incompatible

Zolmitriptan 2.5mg orodispersible tablets sugar free (Necessity Supplies Ltd)

Explore other Zolmitriptan formulations Explore other Zolmitriptan 2.5mg orodispersible tablets sugar free suppliers

Stability Notes

Orodispersible tablet, therefore unsuitable for MCA

Provenance

This compatibility recommendation is derived from Zomig Rapimelt 2.5mg orodispersible tablets (Grunenthal Ltd).

Incompatible

Zolmitriptan 2.5mg orodispersible tablets sugar free (Torrent Pharma (UK) Ltd)

Explore other Zolmitriptan formulations Explore other Zolmitriptan 2.5mg orodispersible tablets sugar free suppliers

Stability Notes

Orodispersible tablet, therefore unsuitable for MCA

Provenance

This compatibility recommendation is derived from Zomig Rapimelt 2.5mg orodispersible tablets (Grunenthal Ltd).

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.